First patient implanted with Philips' Duo Venous stent system [Yahoo! Finance]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Yahoo! Finance
The Duo Venous Stent system comprises two stents, Duo Hybrid and Duo Extend. These stents are designed to work together, combining different mechanical properties into a single stent. The stents work together and minimise the risk of fracture and corrosion while serving caudal veins with smaller diameters. The device won premarket approval from the US Food and Drug Administration (FDA) last year, following positive data from the VIVID study (NCT04580160). The 162-subject study met all of its primary safety and efficacy endpoints, with the safety endpoint of 98.7% coming ahead of the 89% target. Erin Murphy, investigator in the VIVID study, carried out the first procedure outside of the clinical trial. Venous stents are small, expandable tubes inserted into veins to keep them open, ensuring proper blood flow and preventing blockages. They are often used to treat deep vein thrombosis (DVT) and CVI. According to a market model on GlobalData's Medical Intelligence Center, the venous
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- Venous Thromboembolism Treatment Market to be Worth $4.40 Billion by 2030 - Exclusive Report by Meticulous Research® [Yahoo! Finance]Yahoo! Finance
- AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval [Yahoo! Finance]Yahoo! Finance
- Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 75% over the last three years [Yahoo! Finance]Yahoo! Finance
- AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- AngioDynamics receives CE Mark approval in Europe for AlphaVac F1885 System [Seeking Alpha]Seeking Alpha
ANGO
Earnings
- 4/4/24 - Miss
ANGO
Sec Filings
- 5/30/24 - Form SC
- 4/9/24 - Form 10-Q
- 4/8/24 - Form 4
- ANGO's page on the SEC website